Cancer Vaccines Co-Targeting HER2/Neu and IGF1R

(1) Background: Human epidermal growth factor receptor 2 (HER2)/neu-driven carcinogenesis is delayed by preventive vaccines able to elicit autochthonous antibodies against HER2/neu. Since cooperation between different receptor tyrosine kinases (RTKs) can occur in human as well as in experimental tumors, we investigated the set-up of DNA and cell vaccines to elicit an antibody response co-targeting two RTKs: HER2/neu and the Insulin-like Growth Factor Receptor-1 (IGF1R). (2) Methods: Plasmid vectors carrying the murine optimized IGF1R sequence or the human IGF1R isoform were used as electroporated DNA vaccines. IGF1R plasmids were transfected in allogeneic HER2/neu-positive IL12-producing murine cancer cells to obtain adjuvanted cell vaccines co-expressing HER2/neu and IGF1R. Vaccination was administered in the preneoplastic stage to mice prone to develop HER2/neu-driven, IGF1R-dependent rhabdomyosarcoma. (3) Results: Electroporated DNA vaccines for murine IGF1R did not elicit anti-mIGF1R antibodies, even when combined with Treg-depletion and/or IL12, while DNA vaccines carrying the human IGF1R elicited antibodies recognizing only the human IGF1R isoform. Cell vaccines co-expressing HER2/neu and murine or human IGF1R succeeded in eliciting antibodies recognizing the murine IGF1R isoform. Cell vaccines co-targeting HER2/neu and murine IGF1R induced the highest level of anti-IGF1R antibodies and nearly significantly delayed the onset of spontaneous rhabdomyosarcomas. (4) Conclusions: Multi-engineered adjuvanted cancer cell vaccines can break the tolerance towards a highly tolerized RTK, such as IGF1R. Cell vaccines co-targeting HER2/neu and IGF1R elicited low levels of specific antibodies that slightly delayed onset of HER2/neu-driven, IGF1R-dependent tumors.

[1]  P. Lollini,et al.  Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis , 2019, BMC Cancer.

[2]  V. Macaulay,et al.  Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies , 2017, Targeted Oncology.

[3]  C. Hatzis,et al.  Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease , 2017, Breast Cancer Research and Treatment.

[4]  N. Sanders,et al.  Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs , 2016, Oncotarget.

[5]  G. Benegiamo,et al.  Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis , 2015, Breast Cancer Research.

[6]  L. Helman,et al.  IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma , 2015, Neoplasia.

[7]  R. Nahta,et al.  Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1 , 2015, Molecular Pharmacology.

[8]  T. Wu,et al.  DNA vaccine for cancer immunotherapy , 2014, Human vaccines & immunotherapeutics.

[9]  E. Jaffee,et al.  Cancer Immunoprevention—The Next Frontier , 2014, Cancer Prevention Research.

[10]  E. Mittendorf,et al.  Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Penichet,et al.  Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2 , 2014, Breast Cancer Research.

[12]  P. Treuting,et al.  A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease , 2013, Cancer Prevention Research.

[13]  P. Lollini,et al.  Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice , 2013, Oncotarget.

[14]  P. Lollini,et al.  Preclinical HER-2 Vaccines: From Rodent to Human HER-2 , 2013, Front. Oncol..

[15]  S. Plymate,et al.  T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity , 2013, Breast Cancer Research and Treatment.

[16]  G. Ciliberto,et al.  Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors , 2013, Journal of Translational Medicine.

[17]  P. Lollini,et al.  Human responses against HER-2-positive cancer cells in human immune system-engrafted mice , 2012, British Journal of Cancer.

[18]  V. Geenen.  THE APPEARANCE OF THE THYMUS AND THE INTEGRATED EVOLUTION OF ADAPTIVE IMMUNE AND NEUROENDOCRINE SYSTEMS , 2012, Acta clinica Belgica.

[19]  A. Martins,et al.  Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives , 2011, Sarcoma.

[20]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[21]  P. Lollini,et al.  A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. , 2010, Cancer research.

[22]  C. Ottensmeier,et al.  DNA vaccines against cancer come of age. , 2010, Current opinion in immunology.

[23]  P. Lollini,et al.  Molecular and cellular biology of rhabdomyosarcoma. , 2009, Future oncology.

[24]  A. Stojadinovic,et al.  The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 , 2009, Clinical Cancer Research.

[25]  P. Musiani,et al.  A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. , 2009, Human gene therapy.

[26]  P. Musiani,et al.  Antimetastatic activity of a preventive cancer vaccine. , 2007, Cancer research.

[27]  Louis M. Weiner,et al.  Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer , 2007, Nature Reviews Cancer.

[28]  Federica Cavallo,et al.  Vaccines for tumour prevention , 2006, Nature Reviews Cancer.

[29]  P. Musiani,et al.  Immunological Prevention of a Multigene Cancer Syndrome , 2004, Cancer Research.

[30]  P. Musiani,et al.  Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent1 , 2004, The Journal of Immunology.

[31]  Piero Musiani,et al.  Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine , 2004, Cancer Research.

[32]  P. Lollini,et al.  Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells , 2004, Cancer Research.

[33]  P. Musiani,et al.  Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. , 2003, Cancer research.

[34]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.

[35]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[36]  P. Glazer,et al.  ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Elizalde,et al.  Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells , 2001, Oncogene.

[38]  P. Lollini,et al.  Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. , 1995, British Journal of Cancer.

[39]  L. Helman,et al.  In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. , 1994, Cancer research.

[40]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[41]  O. Finn,et al.  Cancer immunoprevention. , 2016, Current opinion in immunology.

[42]  Xia Han,et al.  The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. , 2009, Cancer research.

[43]  P. Musiani,et al.  Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. , 2004, Journal of immunology.